Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

 

HIGHLIGHTS DO CONGRESSO EAU 2019

Junte-se aos especialistas internos GSK e acompanhe conosco a cobertura das principais novidades em HPB do EAU 2019.

Fique ligado nas nossas atualizações (Agenda e palestrantes sujeitos a alteração).

 

AGENDA

  

  

  • Manejo de complicações da laparoscopia

    Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Brazil/MP4/2019-03-21-manejo-de-complicacoes-da-laparoscopia-urologia.mp4

    Referências:

    BR/DUTT/0015/19

    PAVLOVICH, CP. et al. Complications of 2,775 Urological Laparoscopic Procedures: 1993 to 2005. The journal of urology, 177(2): 580-585, 2007.

    GERSHAM, A. et al. Complications of Laparoscopic Nephrectomy in 185 Patients: A Multi-Institutional Review. The journal of urology, 154(2), 479-483, 1995.

    MERANEY, AM. et al. Vascular and Bowel Complications During Retroperitoneal Laparoscopic Surgery. The journal of urology, 168(5): 1941-1944, 2002.

    FAHLENKAMP, D. et al. complications of laparoscopic procedures in urology: experience with 2,407 procedures at 4 german centers. The journal of urology, 162 (3 part 1), 765-771, 1999.

    BERTOLLO, R. et al. Current Status of Three-Dimensional Laparoscopy in Urology: An ESUT Systematic Review and Cumulative Analysis, 32(11): 1021–1027, 2018.

    LENFANT, L. et al. Perioperative outcomes and complications of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy for bladder cancer: a real-life, multi-institutional french study. World J Urol, 36(11): 1711-1718, 2018.

    TAN, TW. et al. Safe transition from extracorporeal to intracorporeal urinary diversion following robot-assisted cystectomy: a recipe for reducing operative time, blood loss and complication rates. World J Urol. 37(2): 367–372, 2019.

     

  

  • Casos clínicos e o tratamento individualizado

    Referências:

    VANDONINCK, V. et al. Percutaneuos Tibial Nerve Stimulation in the treatment of Overactive Bladder: Urodynamic Data. Neurourology and Urodynamics, 22: 227-232, 2003.

    GRAVAS, S. et al. Management of Non-neurogenic Male LUTS. European association of urology. Disponível em: <https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/>. Acesso em: 22 mar. 2019.

    PEYRONNET, B. et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Parkinsonism and Related Disorders, 57: 22–26, 2018.

    HO, C. et al. Intravesical Botulinum Toxin for Adults with Non-Neurogenic Bladder Conditions: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines. CADTH, 2018.

    FINAZZI-AGRÒ, E. et al. Percutaneous Tibial Nerve Stimulation Produces Effects on Brain Activity: Study on the Modifications of the Long Latency Somatosensory Evoked Potentials. Neurourology and Urodynamics, 28(4):320-4, 2009. 

    CHAPPLE, CR. et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. 72(3): 389-399, 2017.

    BUNNIRAN, S. et al. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments. Neurourology and Urodynamics. 37:177–185, 2018.

    HEESAKKERS, JPFA. et al. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints. 37(3): 1060-1067, 2018.

    RUDOLPH, JL. et al. The Anticholinergic Risk Scale and Anticholinergic Adverse Effects in Older Persons. Arch Intern Med, 168(5): 508-513, 2008.

    CRISPO, JAG. et al. Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease. PLoS ONE 11(3): e0150621, 2016.

    GRAY, SL. et al. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study. JAMA Intern Med. 175(3): 401-407, 2015.

    EHRT, U. et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry, 81(2): 160-5, 2010.

    MARCELISSEN, T. et al. Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand? Eur Urol Focus. 2018. Epub.

    TROYA, S. et al. Mirabegron is a safe and effective treatment for Parkinson’s disease patients with storage symptoms refractory to antimuscarinics. In: ICS, 2016, Tóquio. S27 ePoster Station 3. Abstract 497. Disponível em: <https://www.ics.org/Abstracts/Publish/326/000497.pdf>. Acesso em: 22 mar. 2019.

    GUBBIOTTI, M. et al. The use of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease. In: EAU, 32, 2017. Londres. Abstract 157. Disponível em: <http://eau17.uroweb.org/resource-centre/results/abstract/1caace36/>. Acesso em: 22 mar. 2019.

     

HPB = Hiperplasia prostática benigna
LUTS = Sintomas do trato urinário inferior
 

CONHEÇA O TIME